Back to discover
Disease

bone Paget's disease

Also known as Paget disease of bone, Paget's bone disease, Paget's disease of bone, Paget's disease of the bone+6 more

Paget disease of bone, Paget's bone disease, Paget's disease of bone, Paget's disease of the bone, Pagets disease (bone), bone Paget's disease, osseous Paget's disease, osteitis deformans, Paget's disease, familial Paget's disease of bone.

12
Associated genes
2
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Zoledronic acidapproved

Approval — Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fract… (2005)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2005emaApproval — Zoledronic acid· Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. Treatment of Paget's disease of the bone. source ↗
Safety updates
2024emaMarket withdrawal — Zoledronic acid· 4 mg / 5 ml and 4 mg / 100 ml: Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. Treatment of adult patients with tumour-induced hypercalcaemia (TIH). 5 mg / 100 ml: Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: in post-menopausal women; in men; at increased risk of fracture. Treatment of Paget's disease of the bone in adults. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SQSTM10.77TNFRSF11A0.61ZNF6870.60CALCR0.48OPTN0.44CDCP10.36SIGLEC150.33DCSTAMP0.33GFRA10.31RAPH10.31ALDH1B10.30PKP40.30

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Sequestosome-1via SQSTM10.77Tumor necrosis factor receptor superfamily member 11Avia TNFRSF11A0.61

Reference

Authoritative identity, definition & identifiers.

Synonyms

Paget disease of bone, Paget's bone disease, Paget's disease of bone, Paget's disease of the bone, Pagets disease (bone), bone Paget's disease, osseous Paget's disease, osteitis deformans, Paget's disease, familial Paget's disease of bone

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.